File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oncological outcome after free jejunal Xap reconstruction for carcinoma of the hypopharynx

TitleOncological outcome after free jejunal Xap reconstruction for carcinoma of the hypopharynx
Authors
KeywordsCarcinoma of hypopharynx
Free jejunal Xap
Radiation tolerance
Issue Date2012
PublisherSpringer Verlag.
Citation
European Archives Of Oto-Rhino-Laryngology, 2012, v. 269 n. 7, p. 1827-1832 How to Cite?
AbstractIt has been a common practice among the oncologist to reduce the dosage of adjuvant radiotherapy for patients after free jejunal Xap reconstruction. The current aims to study potential risk of radiation to the visceral Xap and the subsequent oncological outcome. Between 1996 and 2010, consecutive patients with carcinoma of the hypopharynx requiring laryngectomy, circumferential pharyngectomy and post-operative irradiation were recruited. Ninety-six patients were recruited. TNM tumor staging at presentation was: stage II (40.6%), stage III (34.4%) and stage IV (25.0%). Median follow-up period after surgery was 68 months. After tumor ablation, reconstruction was performed using free jejunal Xap (60.4%), pectoralis major myocutaneous (PM) Xap (31.3%) and free anterolateral thigh (ALT) Xap (8.3%). All patients underwent adjuvant radiotherapy within 6.4 weeks after surgery. The mean total dose of radiation given to those receiving cutaneous and jejunal Xap reconstruction was 62.2 Gy and 54.8 Gy, respectively. There was no secondary ischaemia or necrosis of the Xaps after radiotherapy. The 5-year actuarial loco-regional tumor control for the cutaneous Xap and jejunal Xap group was: stage II (61 vs. 69%, p = 0.9), stage III (36 vs. 46%, p = 0.2) and stage IV (32 vs. 14%, p = 0.04), respectively. Reduction of radiation dosage in free jejunal group adversely aVects the oncological control in stage IV hypopharyngeal carcinoma. In such circumstances, tubed cutaneous Xaps are the preferred reconstructive option, so that full-dose radiotherapy can be given. © Springer-Verlag 2011.
Persistent Identifierhttp://hdl.handle.net/10722/144586
ISSN
2015 Impact Factor: 1.627
2015 SCImago Journal Rankings: 0.755
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, JYWen_HK
dc.contributor.authorChow, VLYen_HK
dc.contributor.authorChan, RCLen_HK
dc.contributor.authorLau, GISKen_HK
dc.date.accessioned2012-02-03T06:15:03Z-
dc.date.available2012-02-03T06:15:03Z-
dc.date.issued2012en_HK
dc.identifier.citationEuropean Archives Of Oto-Rhino-Laryngology, 2012, v. 269 n. 7, p. 1827-1832en_HK
dc.identifier.issn0937-4477en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144586-
dc.description.abstractIt has been a common practice among the oncologist to reduce the dosage of adjuvant radiotherapy for patients after free jejunal Xap reconstruction. The current aims to study potential risk of radiation to the visceral Xap and the subsequent oncological outcome. Between 1996 and 2010, consecutive patients with carcinoma of the hypopharynx requiring laryngectomy, circumferential pharyngectomy and post-operative irradiation were recruited. Ninety-six patients were recruited. TNM tumor staging at presentation was: stage II (40.6%), stage III (34.4%) and stage IV (25.0%). Median follow-up period after surgery was 68 months. After tumor ablation, reconstruction was performed using free jejunal Xap (60.4%), pectoralis major myocutaneous (PM) Xap (31.3%) and free anterolateral thigh (ALT) Xap (8.3%). All patients underwent adjuvant radiotherapy within 6.4 weeks after surgery. The mean total dose of radiation given to those receiving cutaneous and jejunal Xap reconstruction was 62.2 Gy and 54.8 Gy, respectively. There was no secondary ischaemia or necrosis of the Xaps after radiotherapy. The 5-year actuarial loco-regional tumor control for the cutaneous Xap and jejunal Xap group was: stage II (61 vs. 69%, p = 0.9), stage III (36 vs. 46%, p = 0.2) and stage IV (32 vs. 14%, p = 0.04), respectively. Reduction of radiation dosage in free jejunal group adversely aVects the oncological control in stage IV hypopharyngeal carcinoma. In such circumstances, tubed cutaneous Xaps are the preferred reconstructive option, so that full-dose radiotherapy can be given. © Springer-Verlag 2011.en_HK
dc.languageengen_US
dc.publisherSpringer Verlag.en_US
dc.relation.ispartofEuropean Archives of Oto-Rhino-Laryngologyen_HK
dc.rightsThe original publication is available at www.springerlink.comen_US
dc.subjectCarcinoma of hypopharynxen_HK
dc.subjectFree jejunal Xapen_HK
dc.subjectRadiation toleranceen_HK
dc.titleOncological outcome after free jejunal Xap reconstruction for carcinoma of the hypopharynxen_HK
dc.typeArticleen_HK
dc.identifier.emailChan, JYW: jywchan1@hku.hken_HK
dc.identifier.authorityChan, JYW=rp01314en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s00405-011-1836-zen_HK
dc.identifier.scopuseid_2-s2.0-84864931890en_HK
dc.identifier.hkuros198322en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84864931890&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume269en_HK
dc.identifier.issue7en_HK
dc.identifier.spage1827en_HK
dc.identifier.epage1832en_HK
dc.identifier.isiWOS:000304700600015-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridChan, JYW=27171772200en_HK
dc.identifier.scopusauthoridChow, VLY=36807611300en_HK
dc.identifier.scopusauthoridChan, RCL=54399925900en_HK
dc.identifier.scopusauthoridLau, GISK=54400445600en_HK
dc.identifier.citeulike10063405-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats